Health
Inflammation marker linked to increased fatigue in prostate cancer patients treated with ADT – News-Medical.Net
Prostate cancer is one of the most common cancers among men in the U.S. For many patients, hormone therapy is a treatment option.
Prostate cancer is one of the most common cancers among men in the U.S. For many patients, hormone therapy is a treatment option. This type of therapy, also called androgen deprivation therapy (ADT), reduces the level of testosterone and other androgens in the body. Lowering androgen levels can make prostate cancer cells grow more slowly or shrink tumors over time. However, patients receiving ADT often experience higher levels of fatigue, depression and cognitive impairment.
Moffitt Cancer Center…
-
Noosa News16 hours agoHow Lily Steele-Park took her rapist to court and won
-
Business21 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General22 hours agoRush to buy homes before rate cuts send prices soaring
-
Business19 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025